By Dr. Chinta Sidharthan New research highlights how elevated levels of the iron-regulating hormone hepcidin contribute to ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Mice showing the first symptoms of a psoriasis-like phenotype were injected with anti-VEGF antibodies (n = 12) or an IgG isotype control (n = 8) every 48 hours for 8 days. By days 23–24, skin ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to ...

Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of ...

Psoriasis and psoriatic arthritis (PsA) are both psoriatic diseases, which means they are related. Psoriasis increases your risk of PsA, but this doesn't mean you will get it.